Lavonas EJ, Burnham RI, Schwarz J, et al. - Researchers conducted a post-hoc subgroup analysis of data from a multi-center double-blinded clinical trial of Fab antivenom (FabAV) vs placebo to examine copperhead snake (Agkistrodon contortrix) envenomation patients managed with and without the use of antivenom for their time course of recovery. Further, they examined how age, sex, anatomic site of envenomation, initial severity of envenomation, and geographic region influence this time course. In this study, they included 72 patients, which comprised of 44 who received FabAV. Compared with female victims of copperhead snake envenomation, males victims exhibited slightly better recovery. However, there was no significant difference in response to Fab antivenom in adult vs adolescent patients, patients with upper vs lower extremity envenomation, and patients with initially mild vs moderate envenomation signs.